Bai C, Xin X, Yang Y, Qu F, Fan Z
Front Oncol. 2025; 14:1497272.
PMID: 40051607
PMC: 11883444.
DOI: 10.3389/fonc.2024.1497272.
Rala de Paula B, Crocamo S, Bines J
Transl Breast Cancer Res. 2024; 4:8.
PMID: 38751458
PMC: 11093056.
DOI: 10.21037/tbcr-22-41.
Albers F, Lou M, Dashti S, Swain C, Rinaldi S, Viallon V
Cancer Causes Control. 2024; 35(6):921-933.
PMID: 38363402
PMC: 11130059.
DOI: 10.1007/s10552-024-01856-6.
Dou H, Li F, Wang Y, Chen X, Yu P, Jia S
Diagn Pathol. 2024; 19(1):5.
PMID: 38178166
PMC: 10765627.
DOI: 10.1186/s13000-023-01433-6.
Li C, Hui Y, Wei X, Yao P, Jia Y, Liu M
Am J Cancer Res. 2023; 13(6):2234-2253.
PMID: 37424799
PMC: 10326595.
Single progesterone receptor-positive phenotype has the similar clinicopathological features and outcome as triple-negative subtype in metastatic breast cancer.
Luo Y, Pu H, Li F, Qian S, Chen J, Zhao X
Front Oncol. 2023; 13:1029648.
PMID: 36910652
PMC: 9998980.
DOI: 10.3389/fonc.2023.1029648.
An update on the pathological classification of breast cancer.
Rakha E, Tse G, Quinn C
Histopathology. 2022; 82(1):5-16.
PMID: 36482272
PMC: 10108289.
DOI: 10.1111/his.14786.
CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3.
Porras L, Gorse F, Thiombane N, Gaboury L, Mader S
Cancers (Basel). 2022; 14(21).
PMID: 36358871
PMC: 9657334.
DOI: 10.3390/cancers14215453.
The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S, Boukansa S, Benbrahim Z, Mellas N, Fdili Alaoui F, Melhouf M
Breast J. 2022; 2022:9238804.
PMID: 35711896
PMC: 9187286.
DOI: 10.1155/2022/9238804.
Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.
Zheng H, Ge C, Lin H, Wu L, Wang Q, Zhou S
Int J Clin Oncol. 2022; 27(7):1145-1153.
PMID: 35397755
DOI: 10.1007/s10147-022-02158-0.
Oncofertility and Reproductive Counseling in Patients with Breast Cancer: A Retrospective Study.
Zaami S, Melcarne R, Patrone R, Gullo G, Negro F, Napoletano G
J Clin Med. 2022; 11(5).
PMID: 35268402
PMC: 8911138.
DOI: 10.3390/jcm11051311.
Oral Contraceptive Use and Breast Cancer Risk According to Molecular Subtypes Status: A Systematic Review and Meta-Analysis of Case-Control Studies.
Baranska A, Dolar-Szczasny J, Kanadys W, Kinik W, Ceglarska D, Religioni U
Cancers (Basel). 2022; 14(3).
PMID: 35158842
PMC: 8833678.
DOI: 10.3390/cancers14030574.
The Role of Progesterone Receptors in Breast Cancer.
Li Z, Wei H, Li S, Wu P, Mao X
Drug Des Devel Ther. 2022; 16:305-314.
PMID: 35115765
PMC: 8801368.
DOI: 10.2147/DDDT.S336643.
Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients.
Ahn J, Choi S, Park J, Kim J, Park H, Kim S
Cancers (Basel). 2021; 13(19).
PMID: 34638491
PMC: 8508141.
DOI: 10.3390/cancers13195007.
Is oestrogen receptor-negative/progesterone receptor-positive (ER-/PR+) a real pathological entity?.
Onitilo A, Engel J, Joseph A, Li Y
Ecancermedicalscience. 2021; 15:1278.
PMID: 34567263
PMC: 8426004.
DOI: 10.3332/ecancer.2021.1278.
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y
JAMA Netw Open. 2020; 3(1):e1918160.
PMID: 31899528
PMC: 6991239.
DOI: 10.1001/jamanetworkopen.2019.18160.
Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.
Wu N, Fu F, Chen L, Lin Y, Yang P, Wang C
Clin Transl Oncol. 2019; 22(4):474-485.
PMID: 31222450
DOI: 10.1007/s12094-019-02149-0.
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H
Oncologist. 2018; 24(2):165-171.
PMID: 30171067
PMC: 6369957.
DOI: 10.1634/theoncologist.2018-0176.
Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining.
Kuroda H, Muroi N, Hayashi M, Harada O, Hoshi K, Fukuma E
Breast Cancer. 2018; 26(2):249-254.
PMID: 30066060
PMC: 6394606.
DOI: 10.1007/s12282-018-0898-9.
Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.
Ge W, Clendenen T, Afanasyeva Y, Koenig K, Agnoli C, Brinton L
Int J Cancer. 2018; 142(11):2215-2226.
PMID: 29315564
PMC: 5922424.
DOI: 10.1002/ijc.31249.
